Kornimate/medical-research-clean huggingface dataset:
urosepsis in patients with urinary tract calculi receiving surgical intervention

Conditions: Urosepsis; Urinary Tract Stone

Summary: urosepsis is one of major cause of the overall sepsis leading to high morbidity and mortality, which commonly resulted from urinary tract calculi. the investigator aim to identified the incidence and risk factors of urosepsis in the patients with urinary tract calculi underwent surgical intervention in tertiary-care university hospital.

sepsis is one of the leading cause of death of hospitalized patients in thailand. urosepsis or sepsis which originate from urinary tract infection was reported around 9-31% of the overall sepsis syndrome. urinary tract calculi requiring surgical procedure was reported as a common cause of urinary tract infection. therefore, the investigators aimed to identified the incidence and risk factors of urosepsis in the patients with urinary tract calculi underwent surgical intervention in tertiary-care university hospital. moreover, the patients with sepsis syndrome will be suffered from many complications such as acute respiratory distress syndrome, acute kidney injury, etc. currently, there were many early waring scores to predict the risk of complications to help promptly treatment and decrease the severity. the investigator would like to compare the systemic inflammatory response syndrome (sirs) criteria,modified early warning score (mews) and quick sequential organ failure assessment (qsofa) score to the prediction of postoperative complications in this group of patients. the last primary objective of this study is to follow the course of the patients diagnosed as urosepsis if they had been treated properly according to the sepsis bundle guideline and their outcome.

Eligibility criteria:
inclusion criteria: - adult patients with urinary tract calculi requiring surgical procedure exclusion criteria: - incomplete data
the role of fructose and uric acid in the development of obesity and metabolic syndrome

Conditions: Overweight and Obesity; Metabolic Syndrome; Hyperuricemia

Summary: the purpose of this study is to determine if a low fructose intake could have an impact on weight loss, uric acid levels and the components of the metabolic syndrome (glucose, cholesterol, triglycerides, insulin resistance, high blood pressure).

overweight and obesity are now considered a growing public health problem in mexico and worldwide. this epidemic has been attributed to dietary fructose consumption. although experimental models have demonstrated a role of fructose in the development of obesity, metabolic syndrome and kidney disease, data in human models is lacking. the purpose of this study is to determine if a low fructose intake could have an impact on the components of the metabolic syndrome. the primary endpoint will be to determine the impact of low fructose on weight loss. secondary endpoints will evaluate the impact of low fructose diet on blood pressure and cardiovascular biochemical profile. if fructose is a causal pathway to obesity and metabolic syndrome, it may represent an important target to mitigate this important health problem.

Eligibility criteria:
inclusion criteria: * individuals with a body mass index (bmi) \> 25. bmi defined as: weight in kilograms divided by height (squared) in meters. * residents of mexico city * healthy individuals (no comorbidities or drug prescription for associated chronic diseases) exclusion criteria: * diabetes mellitus type 1 or 2 * severe hypertension (defined as systolic blood pressure \> 160 mmhg and /or diastolic blood pressure \> 100 mmhg) and/or hypertension on pharmacological treatment. * chronic kidney disease (glomerular filtration rate (gfr) \< 60 ml/min) * hepatic damage or advanced disease (clinical, biochemical or histological) * patient receiving any pharmacological treatments for hypercholesterolemia and/or elevated triglycerides. * anemia (any etiology) * malignancy * pregnancy

Keywords: role of fructose in overweight and obesity fructose and metabolic syndrome low fructose diet study effects of fructose in blood pressure and hypertension somatometry changes observed in fructose diets fructose induced overweight and obesity fructose induced metabolic syndrome fructose induced hyperuricemia
feeding tube in cancer patients

Conditions: Enteral Feeding for Head and Neck Cancer Patients

Summary: the purpose of this study is to compare the quality of life (qol) in head and neck patients who are given the gj tube (which is placed in the bowel) versus those who are given the g-tube (which is placed in the stomach) for prophylactic feeding. the standard of care for patients at princess margaret hospital (pmh) is using gj tubes. patients who agree to be in the study will be randomized to either the gj-tube or the g-tube arm. patients randomized to the g-tube will receive prophylactic intravenous and oral antibiotics prior to insertion of the g-tube. antibiotics will be given for a total of 1 week. a few hours following tube insertion (on return to pmh ward), patients will complete a single item, visual analogue pain scale (vas). patients will remain in hospital for a minimum of 24 hours and until the patient and/or family is able to care for the enteric feeding(ef) device at home. patients randomized to the gj-tube may receive i.v medication during the procedure. all patients will be asked to fill out several questionnaires at different time- points of the study. all patients will have regular assessments to evaluate their overall quality of life, toxicity, and how they respond to treatment during the study. patients will also be assessed after they completed study treatment.

prophylactic enteral feeding tubes are used routinely for nutritional support during intensive radiotherapy or chemoradiotherapy for locally advanced head and neck cancer. typically, tubes remain in place for up to 3-4 months. whether small-bore jejunal (gj) or larger bore gastric (g) tubes are used varies geographically, based on tradition, physician preference and availability of services. feeding tube placement is arranged either prior to the start of rt, or more commonly within the first 2 weeks of rt, prior to the onset of severe mucositis. patients are admitted to hospital for 1-3 days to monitor side effects of the procedure, and to allow our dietetic and nursing staff to provide intensive teaching on the use and care of the tube. feeding tubes are kept in place through the treatment course and removed once patients are able to meet their calorie needs and maintain body weight through oral feeding. on average, feeding tubes are removed approximately 2-3 months after completion of rt; however, approximately 20% of patients may still require enteral feeding at 1 year post-treatment. this study will compare the qol in patients who use the g tube versus the gj tube.

Eligibility criteria:
inclusion criteria: * local regional carcinoma of the oral cavity, pharynx, paranasal sinuses, larynx, cervical esophagus * patients who will receive potentially curative radiotherapy or chemotherapy * patients who are recommended for prophylactic enteral feeding exclusion criteria: * patients who are unable to give consent * patients who have other concurrent active cancer diagnosis * patients with established pharyngeal obstruction and/or presence of an ef device

Keywords: enteral feeding g-tube gj tube
a single dose trial investigating safety and local tolerability of ascending doses of long acting activated recombinant human factor vii in healthy male volunteers

Conditions: Congenital Bleeding Disorder; Haemophilia A; Haemophilia B; Healthy

Summary: this trial is conducted in europe. the aim of this clinical trial is to investigate the safety, local tolerability and pharmacokinetic profile (the determination of the concentration of the administered medication in blood over time) of long acting activated recombinant human factor vii when injected subcutaneously (under the skin).


Eligibility criteria:
inclusion criteria: * caucasian origin * body weight between 50 and 100 kg and a body mass index (bmi) between 18.0 and 28.0 kg/m2 inclusive * smoke less than 10 cigarettes/day or equivalent and willingness to abstain from smoking during the entire duration of trial product administration (9 days) exclusion criteria: * known or suspected allergy to trial product or related products, such as activated recombinant human factor vii (novoseven®) * previous participation in this trial, defined as randomised to receive trial product * evidence of clinically relevant pathology or potential thromboembolic risk as judged by the investigator * known history of atherosclerosis or thromboembolic events * overt bleeding, including from gastrointestinal tract * hepatitis b or c infection * hiv infection * positive test for drugs of abuse
novel approaches to reducing tobacco related harm

Conditions: Smoking; Tobacco Smoking Behavior; Cigarette Smoking

Summary: the purpose of this study is to assess initial reactions to alternative nicotine/tobacco products among smokers living with hiv.

participants will sample 4 alternative nicotine/tobacco products and provide initial reactions to the products.

Eligibility criteria:
inclusion criteria: 1. hiv-infected adults age 18 and older currently receiving hiv care 2. self-report smoking ≥10 cigarettes/day of a brand delivering \>0.5mg nicotine for \>2yrs 3. have afternoon expired co concentrations of ≥10ppm or morning urinary cotinine \>100ng/ml (as measured with nicalert) exclusion criteria: 1. impaired mental status as assessed by observation 2. acute intoxication as measured by breath alcohol level (bal) \> 0 3. current use of nicotine replacement or other pharmacotherapy for smoking cessation 4. previous use of e-cigarettes 5. use of other tobacco products (e.g., chew tobacco, cigars) on \> 10 of the past 30 days 6. unstable hiv or associated comorbidities, as determined by a licensed medical professional. 7. pregnancy (females testing positive for pregnancy and any participants wishing to quit immediately will be referred to community smoking cessation treatment and will be excluded from the study) 8. blood pressure at or above 160/100 or below 90/50 9. heart rate at or above 105 bpm or below 45 bpm
treatment of irinotecan hydrochloride liposome injection ii in china: a real world study of pancreatic cancer patients

Conditions: Pancreatic Cancer

Summary: this study is a multi-center observational study.the start time for data collection is may 1, 2024. patients' baseline and treatment data will be collected under informed concent. the purpose of this case registry study was to evaluate the safety and efficacy of irinotecan hydrochloride liposome injection ii based therapy in chinese patients with pancreatic cancer in the real world by collecting, understanding, and analyzing the etiology, clinical features, treatment pattern, treatment outcomes, and pharmacoeconomics changes in pancreatic cancer patients receiving this regimen.


Eligibility criteria:
inclusion criteria: * patients with pancreatic ductal adenocarcinoma diagnosed by pathology or imaging; * age ≥18 years old, male or female; * patients receiving treatment based on irinotecan hydrochloride liposome injection ii; * the subjects voluntarily joined the study and signed the informed consent. exclusion criteria: * confirmed pregnant or lactating women; * the researchers determined that other conditions were not suitable for inclusion in the study.

Keywords: real word study, irinotecan hydrochloride liposome injection ii, pancreatic cancer
stroke-induced myocardial dysfunction: role of gdf-15 (smog-15) clinical work package

Conditions: Ischemic Stroke

Summary: the aim of this study is to analyze the relationship between the blood biomarker gdf-15 and heart damage after stroke. it is being conducted in france, in the neurology department of the dijon university hospital (burgundy). the research is interventional because a biological blood test will be performed, as well as a heart rhythm recording and several cardiac echograms during the hospitalization of the participants and during the follow-up consultation scheduled 4 to 6 months after the stroke. a total of 130 stroke patients will participate in this study. participation includes 4 visits: * inclusion visit (within 24 hours of the first stroke symptoms) * visit 1 (within 24 to 72 hours of stroke) * visit 2 (within 48 hours of visit 1) * visit 3 (approximately 4-6 months post-stroke)


Eligibility criteria:
inclusion criteria: * adult with acute symptomatic cerebral infarction documented by brain imaging on admission (cerebral angioscan or cerebral mri) * whose first symptoms appeared within 24 hours before inclusion * whose consent to participate in this study was obtained from the patient or a close relative. exclusion criteria: * person with a history of symptomatic stroke, either ischemic or hemorrhagic * anyone with a history of heart disease including: atrial fibrillation or flutter (known or discovered on admission), chronic heart failure, pacemaker, defibrillator, or other cardiac devices * person with acute heart failure, suspected infective endocarditis, stemi, or concurrent pulmonary embolism * a person who is not a member or beneficiary of a social security system * person deprived of liberty * person subject to a legal protection measure (curatorship, guardianship) * person subject to a legal protection measure * pregnant, parturient or breastfeeding woman
corneal epithelial stem cells and dry eye disease

Conditions: Dry Eye Syndromes; Dry Eye; Ocular Inflammation; Ocular Surface Disease; Ocular Discomfort; Blepharitis

Summary: to study of a novel, therapeutic human cells, tissues, and cellular and tissue-based product (hct/p) in the treatment of severe dry eye disease that is failing conventional treatments. this pilot study will carefully observe and monitor each qualifying and willing individual for response to treatment, signs of toxicity and adverse effects from the treatment, and for ability of the treatment to improve comfort and restore vision.

eligible patients presenting with severe dry eye disease that have failed treatment with conventional measures will be screened for inclusion into the study. the treatment will consist of administration of formulated topical eye drops containing cadaveric epithelial stem cell-derived product. these eye drops will be transplanted by topical self-administration by the patient four times daily in both eyes for a three month interval.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of advanced dry eye disease * severe dry eye symptoms despite having tried over a half dozen treatments exclusion criteria: * not willing to undergo clinical trial * unable to comply with treatment regimen

Keywords: stem cell therapy dry eye disease
tissue changes in lumbar multifidus after dry needling in subjects with nonspecific low back pain.

Conditions: Low Back Pain

Summary: finding out if tissue changes (thickness, histogram and shrinkage rate) that occur in the lumbar multifidus after deep dry needling are related to changes in patient's pain and disability.

lower back pain in regarded as the main cause of disability in the world, which has a significant socio-economic impact. deep dry needling is effective in handling such pain and is one of the techniques of choice by physiotherapists. in this area, the use of ultrasound provides information of interest such as length, thickness, diameter, cross-sectional area or muscle volume, among others. objective: finding out if tissue changes (thickness, histogram and shrinkage rate) that occur in the lumbar multifidus after deep dry needling are related to changes in patient's pain and disability. it's a double-blind randomized clinical trial in parallel groups. patients will be randomly divided into 2 groups. one of them will receive dry needling and the other dry needling placebo. the initial, post-needling and a week after evaluations will be performed by a blinded to the intervention therapist.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years. * nonspecific pain in the lumbar region. exclusion criteria: * previous surgery in the lumbosacral spine. * osteoporosis. * needle phobia. * neurogenic pain with positive tests or negative symptoms. * red flags: cauda equina syndrome, sudden weight loss, fracture, cancer, infection or systemic diseases. * pregnancy. * physiotherapy intervention in the 4 weeks prior to the intervention.

Keywords: lower back pain dry needling ultrasound disability
apad2: effects of rehabilitation programme in adapted physical activity (apa) among type 2 diabetics

Conditions: NIDDM

Summary: the principal objective is to assess and analyze the effects of a six month programme in adapted physical activity (apa) on physical activity, compliance, and insulin resistance among type 2 diabetics.

clinical trial with direct individual profit. study phase 2. study center: university hospital grenoble principal investigator: pr. serge halimi sponsor: university hospital grenoble the principal objective is to assess and analyze the effects of a six month programme in adapted physical activity (apa) on physical activity, compliance, and insulin resistance among type 2 diabetics. secondary objectives are to assess and analyze the effects of a six month programme in apa of: * arterial tension * weight, body composition and abdominal perimeter * quality of life * treatment dosage * number of hospitalisation thick a diabetes complication acute for one year and for each patient compare two exercise's intensity: first lactate threshold (sl1) and crossover (pcgl). inclusion criteria: * type 2 diabetics * age \> 40 years * first education in education diabetics department of university hospital grenoble * sedentary patients * hba1c \> 7%- * bmi \> 25 * to be affiliate disease assurance * to give consent written and inform judgment criteria for physical activity compliance: * leisure time physical activity: modifiable activity questionnaire * training note-book judgment criteria for resistance insulin: * crossover (pcgl) * homa and firi index * hba1c programme test: rehabilitation programme in adapted physical activity (apa) programme test period: 6 months study total period: 28 months study period for each patient: 18 months safety criteria: clinical compendium undesirable events

Eligibility criteria:
inclusion criteria: * type 2 diabetics * age \> 40 * first education in the education diabetics department of the university hospital grenoble * sedentary patients * hemoglobin a1c (hba1c) \> 7% * body mass index (bmi) \> 25 * to be affiliated with disease assurance * to give written and informed consent exclusion criteria: * foot sore \< six months * renal disease - proteinuria stage * contraindication for exercise * vo2 max \> 120% wassermann standard * coronary pathology non-stabilization * arteriopathy stage 2 non-compensation * osteo-articular crippling problem * geographically distant

Keywords: adapted physical activity quality of life cardiovascular risk teaching directly observed therapy physical activity
ultrasound guided pericapsular nerve block versus iv sedation analgesia in reduction of shoulder dislocation

Conditions: Perioperative Pain

Summary: when someone experiences a shoulder dislocation, it can be extremely painful. emergency physicians often choose to use conscious sedation to help reduce the pain. however, some patients may not be able to tolerate conscious sedation due to concerns about their ability to breathe properly or the risk of inhaling fluids. a recently developed technique called ultrasound-guided pericapsular nerve group (peng) block is used to block the articular branches of the shoulder and the pericapsular spread around the glenohumeral joint. the peng block is commonly used in hip surgery and is effective in providing motor-sparing analgesic results.

when someone experiences a shoulder dislocation, it can be extremely painful. emergency physicians often choose to use conscious sedation to help reduce the pain. however, some patients may not be able to tolerate conscious sedation due to concerns about their ability to breathe properly or the risk of inhaling fluids. in an ideal scenario, the surgeon could achieve complete pain control and muscle relaxation without compromising the patient's airway. there are various techniques available to facilitate shoulder reduction, including interscalene block, general anesthesia, and intravenous analgesia. all of these methods can help the surgeon ease the patient's pain and reduce the likelihood of complications.1 when choosing the anesthesia method for reducing asd, the top priority is ensuring the patient's comfort through pain management. the anesthesia helps to relax the muscle spasms, making it easier to reduce the asd. the goal is to relocate the shoulder with minimal risk of complications. a recently developed technique called ultrasound-guided pericapsular nerve group (peng) block is used to block the articular branches of the shoulder and the pericapsular spread around the glenohumeral joint. the peng block is commonly used in hip surgery and is effective in providing motor-sparing analgesic results.

Eligibility criteria:
inclusion criteria: * (asa )classes i and ii * patients of either sex, above the age of 18 * patients will undergo dislocated shoulder exclusion criteria: * the patient's refusal to participate * coagulation disorders * allergy to local anesthetic * history of daily opioid intake * patients with cognitive impairments
evaluation of the effects of cross linking on the biomechanical characteristics of skin samples from patients with classic or hypermobile ehlers-danlos syndrome

Conditions: Ehlers-Danlos Syndrome

Summary: the main aim of this study is to evaluate the effect of cross linking on the elasticity of skin samples from patients with non-vascular ehlers-danlos syndrome (heds or ceds).

this is a single-center study based on skin biopsies. the skin biopsies will be taken at the non-vascular ehlers-danlos syndromes reference center at the raymond poincaré hospital (garches), by dr. karelle benistan. this center regularly performs this type of biopsy as part of its routine care, and has set up a fibroblast bank for genethon (authorization for biological collection at genethon: sed bacg n° dc-2021-4628). samples will be transported to the centre de recherche saint-antoine (umr-s 938) where they will be processed, cut and placed on histological slides. atomic force microscopy analyses will be carried out at the laboratoire de réactivité de surface (cnrs/sorbonne university).

Eligibility criteria:
inclusion criteria: * patient aged 18 or over, having read and signed the consent form for participation in the study * patient with classic or hypermobile ehlers-danlos syndrome * regularly followed-up at the non-vascular ehlers-danlos syndrome reference center at garches hospital. exclusion criteria: * patient under court protection, guardianship or curatorship * pregnant or breast-feeding patient * patient not affiliated to the french social security system * impossibility of giving the subject informed information and/or written informed consent: dementia, psychosis, disturbed consciousness, non-french-speaking patient * contraindication to anaesthesia or allergy to local anaesthetic product